We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
Avalo Therapeutics
AVTX
$950M
| $94K | ﹤0.01% |
6
| – | – |
|
|
ZYXI
2877
DELISTED
Zynex
ZYXI
| $94K | ﹤0.01% |
13,079
+176
| +1% | +$1.55K |
|
2878
Prospect Capital
PSEC
$1.13B
| $92K | ﹤0.01% |
14,248
+36
| +0.3% | +$235 |
|
|
RVLP
2879
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $91K | ﹤0.01% |
13,059
+200
| +2% | +$1.07K |
|
|
AXAS
2880
DELISTED
Abraxas Petroleum Corp
AXAS
| $90K | ﹤0.01% |
12,821
-54
| -0.4% | -$348 |
|
|
LEAF
2881
DELISTED
Leaf Group Ltd.
LEAF
| $89K | ﹤0.01% |
22,359
-330
| -1% | -$1.21K |
|
2882
Galectin Therapeutics
GALT
$182M
| $88K | ﹤0.01% |
30,798
+3,468
| +13% | +$12.1K |
|
|
KZR
2883
DELISTED
Kezar Life Sciences
KZR
| $87K | ﹤0.01% |
2,175
-18
| -0.8% | -$554 |
|
2884
Hallador Energy
HNRG
$701M
| $86K | ﹤0.01% |
29,122
-100
| -0.3% | -$307 |
|
2885
Smart Sand
SND
$187M
| $86K | ﹤0.01% |
33,962
+451
| +1% | +$1.11K |
|
|
CFMS
2886
DELISTED
Conformis, Inc. Common Stock
CFMS
| $85K | ﹤0.01% |
2,273
+35
| +2% | +$1.66K |
|
2887
Anavex Life Sciences
AVXL
$294M
| $83K | ﹤0.01% |
32,229
+825
| +3% | +$2.17K |
|
|
EVLO
2888
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $83K | ﹤0.01% |
1,016
+14
| +1% | +$1.57K |
|
2889
Lee Enterprises
LEE
$175M
| $82K | ﹤0.01% |
5,803
+150
| +3% | +$2.67K |
|
|
TEF
2890
DELISTED
Telefonica
TEF
| $81K | ﹤0.01% |
14,470
-272
| -2% | -$1.65K |
|
|
SBBP
2891
DELISTED
Strongbridge Biopharma plc.
SBBP
| $81K | ﹤0.01% |
38,917
+606
| +2% | +$1.16K |
|
2892
Concrete Pumping Holdings
BBCP
$495M
| $80K | ﹤0.01% |
14,706
+1,300
| +10% | +$5.29K |
|
2893
Valhi
VHI
$395M
| $79K | ﹤0.01% |
3,520
-14
| -0.4% | -$321 |
|
2894
EyePoint Inc
EYPT
$1.02B
| $77K | ﹤0.01% |
4,949
-130
| -3% | -$2.32K |
|
2895
Rimini Street
RMNI
$447M
| $76K | ﹤0.01% |
19,525
+600
| +3% | +$2.4K |
|
2896
Neuronetics
STIM
$154M
| $73K | ﹤0.01% |
16,160
+73
| +0.5% | +$454 |
|
|
ICD
2897
DELISTED
Independence Contract Drilling, Inc.
ICD
| $73K | ﹤0.01% |
3,647
+7
| +0.2% | +$125 |
|
|
LOGC
2898
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $73K | ﹤0.01% |
10,200
+200
| +2% | +$1.81K |
|
2899
Cibus
CBUS
$147M
| $72K | ﹤0.01% |
+206
| New | +$51.7K |
|
2900
Cyclerion Therapeutics
CYCN
$15.2M
| $72K | ﹤0.01% |
1,317
+16
| +1% | +$1.49K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.